 | Up a level |
Novak, Urban; Fehr, Martin; Schär, Sämi; Dreyling, Martin; Schmidt, Christian; Derenzini, Enrico; Zander, Thilo; Hess, Georg; Mey, Ulrich; Ferrero, Simone; Mach, Nicolas; Boccomini, Carola; Böttcher, Sebastian; Voegeli, Michèle; Cairoli, Anne; Ivanova, Vanesa-Sindi; Menter, Thomas; Dirnhofer, Stefan; Scheibe, Bernhard; Gadient, Sandra; ... (2023). Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). EClinicalMedicine, 64, p. 102221. Elsevier 10.1016/j.eclinm.2023.102221
Ghilardi, Guido; Pabst Müller, Thomas Niklaus; Jeker, Barbara; Müller, Rouven; Cairoli, Anne; Müller, Antonia M S; Bargetzi, Mario; Hitz, Felicitas; Baldomero, Helen; Heim, Dominik; Schmidt, Adrian; Rossi, Davide; Ghielmini, Michele; Wannesson, Luciano; Lerch, Erika; Samaras, Panagiotis; Schanz, Urs; Passweg, Jakob R; Stussi, Georg; Kleber, Martina; ... (2019). Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone marrow transplantation, 54(7), pp. 1029-1037. Nature Publishing Group 10.1038/s41409-018-0379-y
Hitz, Felicitas; Zucca, Emanuele; Pabst, Thomas; Fischer, Natalie; Cairoli, Anne; Samaras, Panagiotis; Caspar, Clemens B; Mach, Nicolas; Krasniqi, Fatime; Schmidt, Adrian; Rothermundt, Christian; Enoiu, Milica; Eckhardt, Katrin; Berardi Vilei, Simona; Rondeau, Stephanie; Mey, Ulrich (2016). Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. British journal of haematology, 174(2), pp. 255-263. Wiley-Blackwell 10.1111/bjh.14049
Wannesson, Luciano; Bargetzi, Mario; Cairoli, Anne; Cerutti, Alessandra; Heim, Dominik; Hess, Urs; Lerch, Erika; Pabst, Thomas; Renner, Christoph; Samaras, Panagiotis; Zucca, Emanuele (2013). Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leukemia & lymphoma, 54(1), pp. 36-40. London: Informa Healthcare 10.3109/10428194.2012.702903
